As of Jul 31
| +0.08 / +1.57%|
The 5 analysts offering 12-month price forecasts for Endocyte Inc have a median target of 12.00, with a high estimate of 21.00 and a low estimate of 7.00. The median estimate represents a +132.56% increase from the last price of 5.16.
The current consensus among 6 polled investment analysts is to Buy stock in Endocyte Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.